Citi downgraded Cadila Healthcare to 'sell' from 'buy, says Cadila's valuations "have moved well ahead of fundamentals," despite gradual recovery in the sector and improving U.S, a Reuters report suggests.
Meanwhile, a Bloomberg report suggests, Citi downgraded Cadila Healthcare to ‘sell’, however, increased target price of stock by 17% to Rs 1,115.
At 1140 hours, the stock was trading 4% lower at Rs 1,120, erasing most of its losses on the National Stock Exchange (NSE). The stock opened at Rs 1,165 and touched a high of Rs 1,175 in early morning deals on NSE. The counter has seen an over ten-fold jump in trading volumes with a combined around 727,000 shares changed hands so far on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)